Monocytes have diverse roles in tumor development (62), both directly and indirectly as the source of tumor-associated macrophages or dendritic cells, and phenotypically align with monocyte-myeloid-derived suppressor cells that are thought to play key roles in tumor progression (63) Intriguingly, a recent report has identified CD62L+ monocytes being recruited to inflammatory sites through high endothelial venules (64) that are common in cancer vascular networks (65), and several reports have identified changes in the monocyte CD62L expression in inflammatory disease states (66–68). The gene discussed is SELL; the disease is cancer.